Trial
NCT03530293
Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Neurocrine Biosciences
Collaborators
—
Condition
Tourette Syndrome
Intervention
Valbenazine
Why stopped
Futility
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-05-17